Browse
Submit Data
Databases
API
Help

Dataset Information

207 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 1064

Monitoring In Vitro Response of Selenium-Treated Prostate Cells by 1H NMR Spectroscopy

ABSTRACT: Metabolomics analysis was performed on DU145 prostate cancer cells and PNT1A non-tumorigenic prostate cells after treatment with selenomethionine and Se-methylselenocysteine using 800 MHz Bruker NMR spectrometer on 18 cell samples.

INSTRUMENT(S): FT-NMR

ORGANISM(S): Human Homo Sapiens

TISSUE(S): Prostate

DISEASE(S): Cancer

SUBMITTER: Meden Isaac-Lam

PROVIDER: ST000134 | MetabolomicsWorkbench | Tue Jan 13 00:00:00 GMT 2015

REPOSITORIES: MetabolomicsWorkbench

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	mwtab	Other

Items per page:

1 - 1 of 1

Similar Datasets

CLDN3 in prostate cancer exosomes

Project description:Exosomes are an emerging source for biomarkers in various diseases. Prostate cancer is the most frequent cancer in men in industrialized countries. The only biomarker widely used is prostate specific antigen with its clinical relevance suffering from low specificity. To identify novel biomarker candidates for prostate cancer we isolated exosomes from the supernatant of malignant PC3 and benign PNT1A cells, grown under standard culture conditions, using sequential centrifugation and ultracentrifugation. Not to alter the cellular growth conditions an FBS-containing medium was used. As control this medium was also subjected to exosomen isolation. Exosome and control samples were analyzed on an LTQ-Orbitrap XL mass spectrometer and subsequently between 441 and 843 proteins per sample were identified by searching against the SwissProt database. 64 proteins exclusively found in PC3 exosomes were subjected to a scoring system, integrating data from five publicly accessible databases and literature search, to identify potential biomarker candidates. Among these the epithelial tight junction protein claudin-3 achieved the highest score. Retests under serum-free conditions using immunoblotting and immunogold-labeling confirmed the expression of claudin-3 on PC3 exosomes. Levels of circulating claudin-3 directly determined from blood plasma, without prior isolation of exosomes, using ELISA were significantly higher (p=0,038) in metastatic prostate cancer patients (n=15) compared to controls with histologically proven benign prostate hyperplasia (n=15). Our results for the first time describe claudin-3 as a potential biomarker candidate in prostate cancer, easily detectably using liquid biopsies, without need for laborious isolation of exosomes. Further studies including larger patient cohorts in different clinical states of prostate cancer are needed to validate our findings.

2017-04-13 | PXD003651 | Pride

Single cell lipidome analysis of phosphatidylcholines and spingomyelins from prostate cells

Project description:We have developed a high-throughput method for the detection and quantification of a wide range of phosphatidylcholine (PC) and sphingomyelin (SM) species from single cells that combines fluorescence-assisted cell sorting (FACS) with automated chip-based nanoelectrospray ionization (nanoESI) and shotgun lipidomics. Using this method we can detect and perform relative quantitation on more than >50 different PC and SM species from immortalised human cells, and can easily distinguish between tumorigenic and non-tumorigenic prostate cell lines.

2022-10-30 | ST002367 | MetabolomicsWorkbench

Tunable three-dimensional engineered prostate cancer tissues for in vitro recapitulation of heterogeneous in vivo prostate tumor stiffness

Project description:In this study we report the establishment and characterization of a three-dimensional in vitro, coculture engineered prostate cancer tissue (EPCaT) disease model based upon and informed by our characterization of in vivo prostate cancer (PCa) xenograft tumor stiffness. In prostate cancer, tissue stiffness is known to impact changes in gene and protein expression, alter therapeutic response, and be positively correlated with an aggressive clinical presentation. To inform an appropriate stiffness range for our in vitro model, PC-3 prostate tumor xenografts were established. Tissue stiffness ranged from 95 to 6,750 Pa. Notably, xenograft cell seeding density significantly impacted tumor stiffness; a two-fold increase in the number of seeded cells not only widened the tissue stiffness range throughout the tumor, but also resulted in significant spatial heterogeneity. To fabricate our in vitro EPCaT model, PC-3 castration-resistant prostate cancer cells were co-encapsulated with BJ-5ta fibroblasts within a poly(ethylene glycol)-fibrinogen matrix augmented with excess poly(ethylene glycol)-diacrylate to modulate the matrix mechanical properties. Encapsulated cells temporally remodeled their in vitro microenvironment and enrichment of gene sets associated with tumorigenic progression was observed in response to increased matrix stiffness. Through variation of matrix composition and culture duration, EPCaTs were tuned to mimic the wide range of biomechanical cues provided to PCa cells in vivo; collectively, a range of 50 to 10,000 Pa was achievable. Markedly, this also encompasses published clinical PCa stiffness data. Overall, this study serves to introduce our bioinspired, tunable EPCaT model and provide the foundation for future PCa progression and drug development studies.

2022-05-24 | GSE203495 | GEO

Expression profiling of human prostate non-tumorigenic RWPE-1 cells after overexpressing ERG and ETV1, and ERG and ETV1 silencing on prostate cancer cells LNCaP and VCaP, respectively

2013-03-01 | GSE39353 | GEO

microRNA Dysregulation in Human Prostate Cancer Cell Model (M12 and P69)

Project description:An isogenic prostate cancer cell model was used to profile miRNA changes that contribute to the tumorigenic state of prostate cancer. P69 cells are an SV40 large T antigen immortalized cell line that is poorly tumorigenic and non-metastatic. The M12 derivative was derived from an in vivo selection process using nude, athymic mice. Immortalized cells were cultured and used to extract RNA and probed against the human miRNA panel from Exiqon. There were a total of 186 miRNAs that were at least two fold differentially regulated . Two human prostate cancer cell lines were used to evaluate miRNA expression differences contributing to oncogenesis. Two replicates were performed and the data presented as the mean fold difference between P69 and M12.

2013-08-15 | E-GEOD-49520 | biostudies-arrayexpress

microRNA Dysregulation in Human Prostate Cancer Cell Model (M12 and P69)

2013-08-15 | GSE49520 | GEO

Transcription profiling by array of human prostate cancer cells enriched for cell surface markers CD44/CD133/alpha 2 beta 1 integrin

Project description:Self-renewing tumor initiating cells that are capable of differentiation and responsible for tumor growth have been isolated from cancers and cell lines. If such minor populations are associated with tumor progression, understanding molecular pathways that are required for viability and maintenance of these populations will allow to target these pathways to eradicate tumors that are resistant to existing therapies. In this study we enriched for prostate cancer progenitors (Pr. CPM-CM-"M-BM-^@M-BM-^Ys) expressing cell surface markers CD44/CD133/alpha 2 beta 1 integrin in non-adherent serum-free growth conditions maintained as spheres. Cells grown in these conditions have increased in vivo clonogenic and in vivo tumorigenic potential. microarray analysis of cells grown in sphere conditions compared with long term monolayer culture conditions revealed preferential activation of PI3K/AKT pathway in prostate cancer progenitors. PI3K p110 alpha and beta protein levels were high in sphere condition cultured cells, and PTEN knockdown lead to an increase in Pr.CPM-CM-"M-BM-^@M-BM-^Ys, and to increased clonogenic and tumorigenic potential. Inhibition of Akt1 phosphorylation target FoxO3a lead to inhibition of tumorigenic capacity in vivo for prostate cancer cells. Inhibition of PI3K activity by PI3K inhibitor NVP-BEZ235 lead to a selective inhibition of Pr.CPM-CM-"M-BM-^@M-BM-^Ys, nuclear localization of FoxO3a and increase in GADD45a in prostate cancer cells. Taken together our data strongly suggest that PTEN and PI3K/Akt pathways are critical for prostate cancer stem-like cell maintenance and targeting the PI3K signaling by selective inhibitors may give an incredible advancement in prostate cancer treatment. Experiment Overall Design: sphere and monolayer cultures from two different prostate cancer cell lines

2009-01-13 | E-GEOD-10832 | biostudies-arrayexpress

Expression profiling of human prostate non-tumorigenic RWPE-1 cells after overexpressing ERG and ETV1, and ERG and ETV1 silencing on prostate cancer cells LNCaP and VCaP, respectively

Project description:Chromosomal rearrangements involving ETS factors, ERG and ETV1, occur frequently in prostate cancer. We here examine human prostate non-tumorigenic RWPE-1 cells with ERG- or ETV1-expressing stable RWPE-1 cell. RWPE-1 stable cell clones overexpressing ERG and ETV1 were grown under normal conditions. Total RNA was extracted from three biological replicates. This was used to hybridize to Affymetrix expression arrays using the HG-U133 Plus 2.0 platform.

2013-03-01 | E-GEOD-39353 | biostudies-arrayexpress

Mast cell-derived SAMD14 is a novel regulator of the human prostate tumor microenvironment

Project description:Mast cells (MCs) are important cellular components of the tumor microenvironment and are significantly associated with poor patient outcomes in prostate cancer and other solid cancers. The promotion of tumor progression partly involves heterotypic interactions between MCs and cancer-associated fibroblasts (CAFs) which combine to potentiate a pro-tumor extracellular matrix and promote epithelial cell invasion and migration. Thus far, the interactions between MCs and CAFs remains poorly understood. To identify molecular changes that may alter resident MC function in the prostate tumor microenvironment, we profiled the transcriptome of human prostate MCs, isolated from patient-matched non-tumor and tumor-associated regions of fresh radical prostatectomy tissue. Transcriptomic profiling revealed a distinct gene expression profile of MCs isolated from prostate tumor regions, including the downregulation of SAMD14, a putative tumor suppressor gene. Proteomic profiling revealed overexpression of SAMD14 in HMC-1 MCs altered the secretion of proteins associated with immune regulation and extracellular matrix processes. To assess MC biological function within a model of the prostate tumor microenvironment, HMC-1-SAMD14+ conditioned media was added to co-cultures of primary prostatic CAFs and prostate epithelium. HMC-1-SAMD14+ secretions were shown to reduce the deposition and alignment of matrix produced by CAFs and suppress pro-tumorigenic prostate epithelial morphology. Overall, our data presents the first profile of human MCs derived from patient prostate cancer specimens and identifies MC-derived SAMD14 as an important mediator of MC phenotype and function within the prostate tumor microenvironment.

2021-03-12 | PXD022782 | Pride